Brief: Cloudbreak Pharma Says Unit Submitted IND Application For CBT-009 To NMPA
06/01/2026 10:21
Jan 6 (Reuters) - Cloudbreak Pharma 2592.HK: UNIT SUBMITTED IND APPLICATION FOR CBT-009 TO CENTER FOR DRUG EVALUATION TO NMPA Further company coverage: 2592.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cloudbreak Pharma
See all newsHong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Hong Kong watchdog tells firms how to cooperate in raids as scrutiny of share sales grows
Brief: Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-358 Ind Application With No Objection
Brief: Cloudbreak Pharma Enters Share Subscription Agreement With Arc Group International For Up To $15 Mln
Brief: Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium